Day One Biopharmaceuticals, Inc. (DAWN)
$21.45
-0.09 (-0.42%)
Rating:
Recommendation:
-
| Symbol | DAWN |
|---|---|
| Price | $21.45 |
| Beta | 0.000 |
| Volume Avg. | 0.54M |
| Market Cap | 1.578B |
| Shares () | - |
| 52 Week Range | 5.44-28.35 |
| 1y Target Est | - |
| DCF Unlevered | DAWN DCF -> | |
|---|---|---|
| DCF Levered | DAWN LDCF -> | |
| ROE | -69.22% | Strong Sell |
| ROA | -58.66% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 5.17% | Neutral |
| P/E | 3.90 | Buy |
| P/B | 4.20 | Strong Buy |
Latest DAWN news
About
Download (Excel)Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.